B.FuX.et al
[4] Conditions that match a drugs FDA approval generally qualify, whether youre using these major GLP-1 brands or similar: Ozempic/Mounjaro: type 2 diabetes [5] Wegovy/Zepbound: obesity (BMI 30) [6] Wegovy/Zepbound: overweight with at least one weight-related condition (BMI 27 to under 30 plus hypertension, high cholesterol, sleep apnea, cardiovascular disease, or type 2 diabetes) [7] Zepbound: obstructive sleep apnea [8] Wegovy: metabolic-associated steatohepatitis (MASH) [9] Off-label conditions can count too when your clinician documents a real diagnosis such as prediabetes, binge eating disorder, or PCOS
Overall, this weight loss treatment offers a comprehensive and personalized approach to achieving lasting success in managing weight and optimizing metabolic health
Lilly removed this from the slide deck, but I managed to snag a picture at the presentation We can see the women in the trial were already at 30.8% weight loss at 80 weeks on the max dose with the 9mg dose only 2% behind and both still losing weight
doi: 10.3390/antiox14101235
Aucun engagement, et la possibilit de commencer ds la consultation si vous le souhaitez